PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study

被引：19

作者：

Arpin, Dominique ^{[2
]}

Charpentier, Marie-Christine ^{[3
,4
]}

Bernardi, Marie ^{[5
]}

Monnet, Isabelle ^{[1
]}

Boni, Aurelie ^{[6
]}

Watkin, Emmanuel ^{[7
]}

Goubin-Versini, Isabelle ^{[8
]}

Lamy, Regine ^{[9
]}

Geriniere, Laurence ^{[10
]}

Geier, Margaux ^{[11
]}

Forest, Fabien ^{[12
]}

Gervais, Radj ^{[13
]}

Madrosyk, Anne ^{[14
]}

Guisier, Florian ^{[15
]}

Serrand, Cecile ^{[2
]}

Locher, Chrystele ^{[16
]}

Decroisette, Chantal ^{[17
]}

Fournel, Pierre ^{[18
]}

Auliac, Jean-Bernard ^{[1
]}

Jeanfaivre, Thierry ^{[19
]}

Letreut, Jacques ^{[20
]}

Doubre, Helene ^{[21
]}

Francois, Geraldine ^{[22
]}

Piton, Nicolas ^{[23
]}

Chouaid, Christos ^{[1
]}

Damotte, Diane ^{[3
,4
]}

机构：

[1] Ctr Hosp Intercommunal Creteil, Dept Pneumol, 40 Ave Verdun, F-94010 Creteil, France

[2] Hop Nord Ouest, Dept Pneumol, Villefranche, France

[3] Cochin Hosp, AP HP, Dept Pathol, Paris, France

[4] Univ Paris 06, Univ Paris Descartes, Inserm U1138, Ctr Rech Cordeliers, Paris, France

[5] Ctr Hosp Pays dAix, Dept Pneumol, Aix En Provence, France

[6] SELAS Cypath, Villeurbanne, France

[7] Hop Nord Ouest, Dept Pathol, Villefranche, France

[8] Ctr Hosp Pontoise, Dept Pathol, Pontoise, France

[9] Ctr Hosp Bretagne Sud, Dept Pneumol, Lorient, France

[10] HCL, Ctr Hosp Lyon Sud, Dept Pneumol, Lyon, France

[11] CHU Morvan, Dept Med Oncol, Brest, France

[12] CHU St Etienne, Hop Nord, Dept Pathol, St Etienne, France

[13] Ctr Francois Bactesse, Dept Med Oncol, Caen, France

[14] Inst Paoli Calmettes, Dept Med Oncol, Marseille, France

[15] CHU Charles Nicolle, Dept Pneumol, Rouen, France

[16] Grand Hop LEst Francilien, Site Meaux, Dept Pneumol, Meaux, Seine & Marne, France

[17] CH Annecy Genevois, Dept Pneumol, Annecy, France

[18] Inst Cancerol Lucien Neuwirth, Dept Med Oncol, St Etienne, France

[19] CHU Angers, Dept Pneumol, Angers, Maine & Loire, France

[20] Hop Europeen, Dept Pneumol, Marseille, France

[21] Hop Foch, Dept Pneumol, Surennes, France

[22] CHU Amiens, Dept Pneumol, Amiens, France

[23] CHU Charles Nicolle, Dept Pathol, Rouen, France

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2020年 / 12卷

关键词：

immunotherapy; inflammatory cells; neuroendocrine carcinoma of the lung; PD-L1; prognosis; MULTICENTER-PHASE-II; PD-L1; EXPRESSION; TUMORS; CHEMOTHERAPY; CRITERIA; CANCER; REPRODUCIBILITY; CISPLATIN;

D O I：

10.1177/1758835920937972

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Few data are available on programmed cell-death-protein-1-ligand-1 (PD-L1) expression on large-cell neuroendocrine carcinomas of the lung (LCNECs). We analyzed PD-L1 expression on tumor (TCs) and inflammatory cells (ICs) from LCNEC patients to assess relationships between this expression, clinical characteristics, and disease outcomes. Methods: PD-L1 expression was determined by immunohistochemistry with monoclonal antibody 22C3 in consecutive LCNEC patients managed in 17 French centers between January 2014 and December 2016. Results: After centralized review, only 68 out of 105 (64%) patients had confirmed LCNEC diagnoses. Median overall survival (OS) (95% CI) was 11 (7-16) months for all patients, 7 (5-10), 21 (10-not reached) and not reached months for metastatic, stage III and localized forms (p = 0.0001). Respectively, 11% and 75% of the tumor samples were TC+ and IC+, and 66% had a TC-/IC+ profile. Comparing IC+versusIC- metastatic LCNEC, the former had significantly longer progression-free survival [9 (4-13)versus4 (1-8) months;p = 0.03], with a trend towards better median OS [12 (7-18)versus9.5 (4-14) months;p = 0.21]. Compared to patients with TC- tumors, those with TC+ LCNECs tended to have non-significantly shorter median OS [4 (1-6.2)versus11 (8-18) months, respectively]. Median OS was significantly shorter for patients with TC+/IC- metastatic LCNECs than those with TC-IC+ lesions (2versus8 months, respectively;p = 0.04). Conclusion: TC-/IC+ was the most frequent PD-L1-expression profile for LCNECs, a pattern quite specific compared with non-small-cell lung cancer and small-cell lung cancer. IC PD-L1 expression seems to have a prognostic role.

引用

页数：8

共 32 条

[1] Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
Adam, J.
Le Stang, N.
Rouquette, I.
Cazes, A.
Badoual, C.
Pinot-Roussel, H.
Tixier, L.
Danel, C.
Damiola, F.
Damotte, D.
Penault-Llorca, F.
Lantuejoul, S.
[J]. ANNALS OF ONCOLOGY, 2018, 29 (04) : 953 - 958
[2] Chauhan Aman, 2018, Oncotarget, V9, P14738, DOI 10.18632/oncotarget.24553
[3] Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial
Christopoulos, P.
Engel-Riedel, W.
Grohe, C.
Kropf-Sanchen, C.
von Pawel, J.
Guetz, S.
Kollmeier, J.
Eberhardt, W.
Ukena, D.
Baum, V.
Nimmrich, I.
Sieder, C.
Schnabel, P. A.
Serke, M.
Thomas, M.
[J]. ANNALS OF ONCOLOGY, 2017, 28 (08) : 1898 - 1902
[4] Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Derks, Jules L.
van Suylen, Robert Jan
Thunnissen, Erik
den Bakker, Michael A.
Groen, Harry J.
Smit, Egbert F.
Damhuis, Ronald A.
van den Broek, Esther C.
Speel, Ernst-Jan M.
Dingemans, Anne-Marie C.
[J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (06)
[5] PD-L1 expression in large cell neuroendocrine carcinoma of the lung
Eichhorn, F.
Harms, A.
Warth, A.
Muley, T.
Winter, H.
Eichhorn, M. E.
[J]. LUNG CANCER, 2018, 118 : 76 - 82
[6] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Eisenhauer, E. A.
Therasse, P.
Bogaerts, J.
Schwartz, L. H.
Sargent, D.
Ford, R.
Dancey, J.
Arbuck, S.
Gwyther, S.
Mooney, M.
Rubinstein, L.
Shankar, L.
Dodd, L.
Kaplan, R.
Lacombe, D.
Verweij, J.
[J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
[7] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Gandhi, L.
Rodriguez-Abreu, D.
Gadgeel, S.
Esteban, E.
Felip, E.
De Angelis, F.
Domine, M.
Clingan, P.
Hochmair, M. J.
Powell, S. F.
Cheng, S. Y. -S.
Bischoff, H. G.
Peled, N.
Grossi, F.
Jennens, R. R.
Reck, M.
Hui, R.
Garon, E. B.
Boyer, M.
Rubio-Viqueira, B.
Novello, S.
Kurata, T.
Gray, J. E.
Vida, J.
Wei, Z.
Yang, J.
Raftopoulos, H.
Pietanza, M. C.
Garassino, M. C.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2078 - 2092
[8] Girard N, GCO TRIAL EXPLORING
[9] The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
Goldstraw, Peter
Crowley, John
Chansky, Kari
Giroux, Dorothy J.
Groome, Patti A.
Rami-Porta, Ramon
Postmus, Pieter E.
Rusch, Valerie
Sobin, Leslie
[J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : 706 - 714
[10] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Hellmann, M. D.
Ciuleanu, T. -E.
Pluzanski, A.
Lee, J. S.
Otterson, G. A.
Audigier-Valette, C.
Minenza, E.
Linardou, H.
Burgers, S.
Salman, P.
Borghaei, H.
Ramalingam, S. S.
Brahmer, J.
Reck, M.
O'Byrne, K. J.
Geese, W. J.
Green, G.
Chang, H.
Szustakowski, J.
Bhagavatheeswaran, P.
Healey, D.
Fu, Y.
Nathan, F.
Paz-Ares, L.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2093 - 2104

← 1 2 3 4 →